Showing 1 - 10 of 80
The College Voor Zorgverzekeringen (CVZ) provides guidance to the Dutch healthcare system on funding and use of new pharmaceutical technologies. This study examined the impact of evidence, process and context factors on CVZ decisions in 2004–2009. A data set of CVZ decisions pertaining to...
Persistent link: https://www.econbiz.de/10010993875
This paper describes and discusses the development and use of health technology assessment (HTA) in five Central and Eastern European countries (CEE): Poland, the Czech Republic, Hungary, Romania and Bulgaria. It provides a general snapshot of HTA policies in the selected CEE countries to date...
Persistent link: https://www.econbiz.de/10010993931
Without changes in the current policies, pharmaceutical companies will eventually cease responding to the incentives to develop orphan drugs, because they will increasingly be uncertain whether the drugs, if developed, will be reimbursed. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2014
Persistent link: https://www.econbiz.de/10010993990
Persistent link: https://www.econbiz.de/10008497309
Persistent link: https://www.econbiz.de/10005167149
Persistent link: https://www.econbiz.de/10005615766
Background: The German hospital-to-home discharge management of geriatric patients has long been criticized. The implementation of the American Transitional Care Model (TCM) could help to reduce readmissions and costs. The objective of this review was to check the scientific evidence of the...
Persistent link: https://www.econbiz.de/10014497474
Background: Evidence suggests benefits of orthogeriatric co-management (OGCM) for hip fracture patients. Yet, evidence on cost-effectiveness is limited and based on small datasets. The aim of our study was to conduct an economic evaluation of the German OGCM for geriatric hip fracture patients....
Persistent link: https://www.econbiz.de/10014497507
A universal strategy to promote physical activity in primary care has the potential to increase life years lived free from physical disease. There is only weak evidence that a universal intervention strategy might prove cost-effective. </AbstractSection> Copyright The Author(s) 2014
Persistent link: https://www.econbiz.de/10010993819
This study investigated the cost-effectiveness of leflunomide (LEF) compared to methotrexate (MTX) and sulfasalazine (SSZ) in the United Kingdom. A Markov model was constructed using health states defined by Health Assessment Questionnaire score. The model is based on a cohort of patients with...
Persistent link: https://www.econbiz.de/10010993821